ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.

ARGX Argen X SE

350.80
2.30 (0.66%)
30 Abr 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Argen X SE ARGX Euronext Acción Ordinaria
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
2.30 0.66% 350.80 10:40:00
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
349.20 347.20 354.50 350.80 348.50
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
16/4/202400:00GLOBEargenx Data Highlight Evidence that VYVGART and VYVGART..
27/3/202401:00GLOBEargenx Advances Clinical Development of Efgartigimod in..
26/3/202415:00GLOBEargenx Announces Annual General Meeting of Shareholders on..
26/3/202401:00GLOBEargenx Announces Approval of VYVGART (efgartigimod alfa) in..
07/3/202415:01GLOBEargenx Delivers on Promise to Transform Patient Expectations..
29/2/202400:00GLOBEargenx Reports Full Year 2023 Financial Results and Provides..
26/2/202400:00GLOBEargenx to Present at Upcoming Investor Conferences
22/2/202400:00GLOBEargenx to Report Full Year 2023 Financial Results and Fourth..
20/2/202400:00GLOBEargenx Announces FDA Acceptance of Supplemental Biologics..
18/1/202400:00GLOBEargenx Announces Approval of VYVDURA® (efgartigimod alfa and..
08/1/202400:00GLOBEargenx Highlights 2024 Strategic Priorities
02/1/202400:00GLOBEargenx to Present at 42nd Annual J.P. Morgan Healthcare..
20/12/202300:00GLOBEargenx Reports Topline Results from ADDRESS Study of..
28/11/202300:00GLOBEargenx Reports Topline Results from ADVANCE-SC Study of..
16/11/202306:40GLOBEargenx Announces European Commission Approval of..
01/11/202301:00GLOBEargenx Highlights Data Evaluating VYVGART in Neuromuscular..
31/10/202301:00GLOBEargenx Reports Third Quarter 2023 Financial Results and..
24/10/202300:00GLOBEargenx to Report Third Quarter 2023 Financial Results and..
21/9/202300:00GLOBEargenx Announces VYVGART (efgartigimod alfa) Authorized for..
15/9/202300:00GLOBEargenx Announces Positive CHMP Opinion for Subcutaneous..
30/8/202300:00GLOBEargenx to Present at Upcoming Investor Conferences
27/7/202300:00GLOBEargenx Reports Half Year 2023 Financial Results and Provides..
24/7/202315:30GLOBEargenx announces closing of global offering
20/7/202300:00GLOBEargenx to Report Half Year 2023 Financial Results and Second..
19/7/202316:58GLOBEargenx announces full exercise of underwriters’ option to..
18/7/202320:30GLOBEargenx raises $1.1 billion in gross proceeds in a global..
17/7/202315:01GLOBEargenx announces launch of proposed global offering
17/7/202300:00GLOBEargenx Reports Positive Topline Data from ADHERE Study of..
30/6/202308:39GLOBEargenx and Zai Lab Announce Approval of VYVGART®..
20/6/202317:12GLOBEargenx Announces U.S. Food and Drug Administration Approval..
20/6/202300:00GLOBEargenx Initiates Second Cohort of Phase 2 ARDA Study of..
31/5/202300:00GLOBEargenx to Present at Upcoming Investor Conferences
04/5/202300:00GLOBEargenx Reports First Quarter 2023 Financial Results and..
03/5/202315:01GLOBEargenx announces results of Annual General Meeting of..

Su Consulta Reciente

Delayed Upgrade Clock